

Disclosures

Personal Commercial (2)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Acute Coronary Syndromes
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	General Cardiology

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (2)

Non-Commercial Entity Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
PLx Pharma	Research/Research Grants	Significant (>= \$5,000)	Stable Ischemic Heart Disease
Scott R. MacKenzie Foundation	Research/Research Grants	Significant (>= \$5,000)	General Cardiology

Clinical Trial Enroller (7)

Trial Name	Trial Sponsor	Trial Funding Source
DAPA-HF	AstraZeneca Pharmaceuticals	
EMPACT-MI	Boehringer Ingelheim Pharmaceuticals, Inc	
SOS-AMI	Idorsia Pharmaceuticals Ltd.	
PARAGLIDE	Novartis Corporation	
VICTORION-INITIATE	Novartis Corporation	
VICTORION-PREVENT	Novartis Corporation	
REVERSE-IT	PhaseBio	

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 4/5/2024

[URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement](http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement)

Confidentiality, Disclosure and Assignment Agreement | Signed on 4/5/2024

[URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement](http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement)

Embargo | Signed on 4/5/2024

[URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement](http://disclosures.acc.org/Public/Definition/EmbargoAgreement)

On-Going Obligation Agreement | Signed on 4/5/2024

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.